- Report
- April 2024
- 262 Pages
From €5439EUR$5,600USD£4,692GBP
- Report
- June 2019
- 95 Pages
United States
From €1020EUR$1,050USD£880GBP
- Report
- August 2022
- 104 Pages
From €2040EUR$2,100USD£1,760GBP
€2914EUR$3,000USD£2,514GBP
- Report
- August 2022
- 112 Pages
Middle East, Africa
From €2040EUR$2,100USD£1,760GBP
€2914EUR$3,000USD£2,514GBP
- Report
- August 2022
- 124 Pages
Asia Pacific
From €2040EUR$2,100USD£1,760GBP
€2914EUR$3,000USD£2,514GBP
- Report
- July 2022
- 120 Pages
North America
From €2040EUR$2,100USD£1,760GBP
€2914EUR$3,000USD£2,514GBP
- Report
- July 2022
- 132 Pages
Europe
From €2040EUR$2,100USD£1,760GBP
€2914EUR$3,000USD£2,514GBP
- Report
- July 2022
- 122 Pages
United Kingdom
From €2040EUR$2,100USD£1,760GBP
€2914EUR$3,000USD£2,514GBP
- Report
- March 2022
- 198 Pages
Global
From €3093EUR$3,185USD£2,669GBP
€4419EUR$4,550USD£3,812GBP
- Report
- June 2021
- 44 Pages
Global
€21368EUR$22,000USD£18,433GBP
- Report
- September 2019
- 13 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- September 2019
- 12 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- September 2019
- 13 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- September 2019
- 12 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- September 2019
- 13 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- October 2022
- 120 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Report
- October 2021
- 120 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Clinical Trials
- October 2020
- 120 Pages
Global
From €10679EUR$10,995USD£9,212GBP
- Report
- January 2021
- 201 Pages
Global
From €3497EUR$3,600USD£3,016GBP
- Report
- January 2021
- 79 Pages
Asia Pacific
From €1457EUR$1,500USD£1,257GBP
The Meningococcal Vaccine is a type of vaccine used to protect against meningococcal disease, a serious and potentially fatal infection caused by the bacterium Neisseria meningitidis. It is recommended for adolescents and young adults, as well as for those at increased risk of infection, such as travelers to certain countries and those with certain medical conditions. The vaccine is available in both conjugate and polysaccharide forms, and is typically administered in two or three doses.
The Meningococcal Vaccine market is part of the larger Infectious Diseases Drugs market, which includes a range of treatments for various infectious diseases. The Meningococcal Vaccine market is expected to grow in the coming years, driven by increasing awareness of the disease and the availability of new vaccines.
Some companies in the Meningococcal Vaccine market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novartis. Show Less Read more